COMP <GO>
PRCT vs JNJ // GROSS PROFIT MARGIN
PROCEPT BioRobotics Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PRCT 1
— JNJ 9
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $20.30 (+0.50%) • MKT CAP: $1.16B
gross-margins
63.70%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRCT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRCT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 63.70% | 67.90% | -4.20 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.02% | 2.97% | -7.99 | JNJ | /fcf-yield <GO> |
| Operating Margin | -33.70% | 34.70% | -68.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 37.20% | 6.00% | +31.20 | PRCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 5.59 | -1.61 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 62.1 | -11.38 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.16B | $662.49B | -$661.33B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRCT REV | JNJ REV | PRCT GROSS % | JNJ GROSS % | PRCT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $308.1M | $94.19B | 63.7% | 67.9% | -$58.3M | $19.70B |
| FY 2024 | $224.5M | $88.82B | 61.1% | 69.1% | -$103.6M | $19.84B |
| FY 2023 | $136.2M | $85.16B | — | — | -$108.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRCT // BETA —
JNJ // BETA 1.08